Biocad

5 results found.

Rheumatoid Arthritis Clinical Trial using Rituximab

Biocad - Recruiting 18 years to 80 years.
- Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies.
Rituximab

Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma, Clinical Trial using rituximab

Biocad - Recruiting 18 years to 95 years.
- A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma.
rituximab

HER2-positive Metastatic Breast Cancer Clinical Trial using Trastuzumab; Paclitaxel

Biocad - Recruiting 18 years to 70 years.
- International Multicenter Randomized Double Blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptinr (F. Hoffmann-La Roche Ltd, Switzerland) Used With Paclitaxel in the First-line Treatment of HER2-positive Metastatic Breast Cancer Patients.
Trastuzumab; Paclitaxel

Hepatitis, or Hepatitis C Clinical Trial using Algeron; Pegasys

Biocad - Recruiting 18 years to 70 years.
- An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C.
Algeron; Pegasys

Non-small Cell Lung Cancer Clinical Trial using Bevacizumab; Paclitaxel; Carboplatin

Biocad - Recruiting 18 years to 70 years.
- International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastinr (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients.
Bevacizumab; Paclitaxel; Carboplatin